Genmab A GMAB
NASDAQ GMAB
$39.57 +0.50 (+1.28%)
At close: Oct 21, 2026 · 4:00 PM EDT

Genmab A (GMAB) Gross Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported Gross Margin of 92.73% for the quarter ended Jun 30, 2026, down 0.02 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) Gross Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's Gross Margin came in at 93.63%; for the year ended Dec 31, 2025, it came in at 93.60%, down 1.82 percentage points from the prior year.

  • By year, Gross Margin came in at 95.42% in the year ended Dec 31, 2024 (+31.26 pp) and 64.16% in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 68.19%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 74.74%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 73.54%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 78.02%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 83.60%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 72.04%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 79.76%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 72.78%
10 Genmab A 2.56 Bn -2.81 Bn 1.07 Bn 92.73%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 92.73%
Mar 31, 2026 92.75%
Sep 30, 2025 94.32%
Jun 30, 2025 93.84%
Mar 31, 2025 94.13%
Sep 30, 2024 95.10%
Jun 30, 2024 96.41%
Mar 31, 2024 95.52%
Sep 30, 2023 98.32%
API Access

Genmab A Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY